ArticleEndocrine connections2026
Association between serum meteorin-like protein and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: a cross-sectional study.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The objective of this study is to investigate the association between serum meteorin-like protein (Metrnl) and metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes mellitus (T2DM) and evaluate its incremental discriminatory value beyond the Hepatic Steatosis Index (HSI). Methods: This cross-sectional study enrolled 198 T2DM patients (110 T2DM-only; 88 T2DM + MASLD). Metrnl levels were measured via ELISA. Multivariable and ordinal logistic regressions assessed the independent association between the Metrnl and MASLD presence and ultrasonographic severity, adjusting for clinical confounders. Discriminatory performance was evaluated using ROC analyses and likelihood-ratio tests. Results: Serum Metrnl was significantly lower in the T2DM + MASLD group versus T2DM-only (0.65 (0.46, 0.82) vs 0.75 (0.62, 0.88) ng/mL, P = 0.007). After full adjustment for adiposity, lipids, liver enzymes, and insulin resistance, lower Metrnl remained independently associated with higher MASLD risk (OR = 0.238, 95% CI: 0.061-0.931, P = 0.039) and greater steatosis severity (P < 0.001). Adding Metrnl to HSI significantly improved the diagnostic model fit (AUC increased from 0.727 to 0.747, P = 0.011). Conclusion: Decreased serum Metrnl is independently associated with the MASLD presence and severity in T2DM, irrespective of obesity and insulin resistance. Metrnl serves as a distinct metabolic correlate, offering modest incremental value in multiparameter risk assessment models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.